Thanks to an FDA grant, the American Society of Addiction Medicine issued the final version of The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. The draft guideline was issued in June 2024.


